3 Medical Stocks to Watch as Q2 Earnings Approach: ABT, JNJ, NVS
The broader market's historic rebound may make it necessary to consider some defensive positions in the portfolio, and these medical stocks fit the bill ahead of their Q2 reports.
| Ticker |
NVS
|
| CIK | 0001114448 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | LICHTSTRASSE 35, BASEL, V8, CH 4056 |
| Website | novartis.com |
| Phone | 01141613241111 |
| CEO | Vasant Narasimhan |
| Employees | 101,700 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
3 Medical Stocks to Watch as Q2 Earnings Approach: ABT, JNJ, NVSThe broader market's historic rebound may make it necessary to consider some defensive positions in the portfolio, and these medical stocks fit the bill ahead of their Q2 reports. Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the impact of generics. Inflation Data and Bank Earnings Kick Off a Crucial Test for MarketsThe big US banks bested Q1 earnings expectations, and many observers expect big boosts to their Q2 trading desk revenues. Bayer Gets FDA Nod for Label Expansion of Kerendia in Heart FailureBAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major conditions. Exploring Analyst Estimates for Novartis (NVS) Q2 Earnings, Beyond Revenue and EPSGet a deeper insight into the potential performance of Novartis (NVS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics. |